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Summary
AIMS: This study evaluated the evolution of the prenatal
diagnosis of congenital heart disease (CHD) between 2003
and 2008 and its repercussion for the CHD prevalence
rate at birth in a well-defined population (Canton of Vaud,
Switzerland).
METHODS AND RESULTS: All 572 cases of CHD repor-
ted in the Eurocat Registry of Vaud-Switzerland between
1.5.2003 and 31.12.2008 were analysed and compared with
the cases in our clinical database. CHD cases were divided
into five different groups according to heart disease sever-
ity. The prenatal detection rates increased significantly
between 2003 and 2008, with a mean detection rate of
25.2%. There was a significantly higher rate of prenatal
diagnosis in the first four groups of CHD severity, with the
highest detection rate (87.5%) found in the group with the
most severe CHD (group 1). In this group, 85.7% of cases
resulted in a termination of pregnancy, and there was a con-
sequent 75% reduction in the prevalence of severe major
cardiac malformation at birth. Detection rates were 66% in
group 2, 68.6% in group 3, and the lowest in groups 4 and
5, with rates of 25.9% and 12.9%, respectively.
CONCLUSION: This study shows that the prenatal detec-
tion rate for CHD increased in a well-defined population
over the study period. Prenatal diagnosis thus has had a ma-
jor impact on patients with the most severe types of CHD
and has resulted in a significant reduction in severe CHD at
birth.
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Introduction
Although there has been increasing interest in the prenatal
diagnosis of congenital heart disease (CHD) over the last
decade, there is little epidemiological evidence regarding
the effectiveness and impact of regionally organised
screening programmes in this field.
Nevertheless, with the introduction of foetal ultrasono-
graphy in the early 1980s and the routine incorporation of
cardiac scanning, it is now possible to diagnose a wide
range of CHDs during foetal life with a high degree of dia-
gnostic accuracy, particularly when the examination is per-
formed at a specialised centre [1].
Several studies have reported an average antenatal CHD
detection rate of 23–28% in the general population [2–4].
Population-based data should, however, be considered sep-
arately from tertiary centres' reports, which cite much high-
er detection rates [5].
Allan et al. reported a decrease in the prevalence of hypo-
plastic left heart syndrome (HLHS) in infancy due to the
impact of prenatal diagnosis [6, 7]. These data were con-
firmed by Bull in 1999 [2].
Carvalho et al. showed that the addition of outflow tract
views to the four-chamber view and operator training res-
ulted in an antenatal detection rate of 75% for major CHD
[8].
Meanwhile, the potential impact of the widespread use of
foetal echocardiography, increased prenatal diagnosis, and
termination of pregnancy (TOP) in cases of foetal anom-
alies on reducing the prevalence of CHD at birth has not
yet been assessed. However, all of these factors are likely
to result in a significant change in the paediatric popula-
tion with congenital cardiac disease, with a major impact
on healthcare costs. Thus, the aim of this study was to ana-
lyse the evolution of prenatal diagnosis of CHD in our loc-
al population and its repercussions for the prevalence rate
of CHD at birth, using the reliable database of the Eurocat
Registry of Vaud-Switzerland [9, 10].
Methods
We performed a retrospective analysis to evaluate the evol-
ution of prenatal diagnosis of CHD and its repercussions
for the prevalence of CHD at birth in the Canton of Vaud,
in south-western Switzerland. The study period was from
1.5.2003 to 31.12.2008. The Canton of Vaud has a popula-
tion of 684,922 and a birth rate of 112/10,000 (2008). The
Eurocat Registry of Vaud-Switzerland provided data on all
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cases of CHD (live births, stillbirths, and TOP) during this
period. EUROCAT is a European network of population-
based registries for the epidemiological surveillance of
congenital anomalies, incorporating more than 1.5 million
births per year in Europe (with a total of 43 registries in 23
countries, covering 29% of European births) [9]. Eurocat
Vaud is one of those registries, covering the Canton of
Vaud [10]. The method of data collection and the Eurocat
membership criteria are well described elsewhere [9–10].
The Eurocat Registry of Vaud uses multiple sources of
information for case ascertainment to cover all outcomes
of congenital anomalies, including live birth, foetal death
from 20 weeks' gestation and TOP. Sources include files
from foetal medicine units, cytogenetic and medical genet-
ic records, neonatology, maternity, paediatric, cardio-pae-
diatric and surgical units, paediatricians in private practise,
and anatomopathological reports.
The data extracted from the registry were pregnancy out-
comes (live births, stillbirths, and TOP), all diagnosed mal-
formations and syndromes, and the time of diagnosis (pren-
atally, at birth or later).
Cases of patent ductus arteriosus (PDA) and patent fora-
men ovale (PFO) and cases considered as variations of nor-
mal were excluded.
The population data were provided by the Swiss federal
statistics database and the Service Cantonal de Recherche
et d'Information Statistiques (SCRIS). Prenatal ultrasound
screening for congenital malformations in Switzerland is
routinely performed in the second trimester, either by a
general obstetrician-gynaecologist or by specialists in
foetal-maternal medicine, with an estimated percentage of
90% of pregnant women undergoing a scan in the Canton
of Vaud. Prenatally suspected cardiac malformations are
most often referred for confirmation to the foetal-maternal
unit of the University Hospital of Vaud in Lausanne, a sec-
ondary and tertiary referral centre for patients living in the
Canton of Vaud. In the present study, a team consisting of
a paediatric cardiologist and specialists in foetal-maternal
medicine performed the cardiac ultrasound investigations.
Every case of CHD was explained and discussed with the
parents by a multidisciplinary team after the examination.
Counselling included an explanation of the normal foet-
al heart, the particular pathology diagnosed, the short-term
outcome of possible interventions, and the long-term clin-
ical condition and quality of life of CHD patients. Co-mor-
bidities, if present, were taken into account in these discus-
sions. Parents were assured of support, regardless of their
final decision.
The obstetricians' teaching programme and postgraduate
training consisted of repeated courses in foetal cardiology
with hands-on training. The in-house training and teaching
of obstetric ultrasonographers was intensified during the
study period to include different cardiac views, with out-
flow tract views added to the four-chamber view.
Moreover, since 2003, the joint presence of obstetricians
and paediatric cardiologists during echocardiographic ses-
sions has permitted direct feedback from and teaching by
the specialised foetal cardiologists. High-resolution ultra-
sound equipment with cineloop technology was used
(Voluson 730 Expert, GE Healthcare, Glattbrugg, CH, from
2003 to March 2007 and Voluson E8 Expert, GE Health-
care, Glattbrugg, CH, since March 2007).
Referral indications for echocardiography were both ma-
ternal and foetal. Maternal referral indications included a
family history of CHD, maternal pathology (e.g., maternal
diabetes), lupus erythematosus, Sjögren's disease, and ex-
posure to toxins. Foetal referral indications included abnor-
mal nuchal translucency, suspected cardiac anomaly, foetal
arrhythmia, and foetal hydrops. All data from the prenatal
cardiac evaluations were recorded in a local database.
Cardiac anomalies diagnosed at primary or secondary
centres and ending in TOP without requiring a referral and
cases observed at tertiary centres outside the canton were
included in the prenatally diagnosed group.
All CHD cases extracted from the local Eurocat database
were analysed and compared with the results of the clinical
database, when available. The cases were then assigned
to one of five different groups based on CHD severity, as
defined in table 1. Foetuses with more than one cardiac
malformation were listed only once and included in the
group corresponding to the most severe malformation. The
outcomes were categorised into the following three groups:
live birth, TOP and intrauterine death. Cases were classi-
fied according to the presence or absence of an associated
chromosomal anomaly. Non-chromosomal cases were clas-
sified as isolated in the absence of an additional major mal-
formation; otherwise, they were classified as multiple. We
compared the overall percentages of prenatally diagnosed
defects during the study period, stratified by severity cat-
egory. We also calculated and compared the overall pre-
valence rates and live birth prevalence rates for all CHD
groups and non-chromosomal CHD groups and for each
group separately.
Statistical analysis was performed using Stata 11 (Stata
Corporation, College Station, TX, USA). The data are ex-
pressed as frequencies, percentages, or means. The prenatal
Table 1: Groups 1–5 were based on the type and severity of CHD. The category definition and associated pathologies in each group are provided.
Group Definition Pathologies included
1 Severe heart disease for which only palliative surgery is available (Fontan-like
circulation)
HLHS, single-ventricle heart
2 Heart disease with immediate severe neonatal morbidity and mortality requiring
early surgery
Transposition of the great arteries
3 Heart disease requiring immediate post-natal care and/or deferred surgical or
interventional correction
Conotruncal abnormalities (tetralogy of Fallot, pulmonary atresia, truncus
arteriosus, double-outlet right ventricle), malalignment VSD, AVSD
4 Heart disease requiring post-natal follow-up Aortic stenosis, isolated discrete coarctation, pulmonary stenosis, Ebstein's
anomaly, large perimembranous VSDs (requiring an operation),
cardiomyopathy, CHD associated with other anomalies
5 Minor CHD with no impact on outcome Small VSDs, ASD II
CHD = congenital heart disease; HLHS = hypoplastic left heart syndrome; AVSD = atrioventricular septal defect; VSD = ventricular septal defect; ASD = atrial septal defect.
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detection rates, overall prevalence rates, and prevalence
rates at birth were compared using Fisher's exact test for
categorical variables. Data with p-values <0.05 were con-
sidered significant.
Results
During the study period, there were 41,573 births in the
Canton of Vaud (Switzerland). The Eurocat Registry of
Figure 1
The percentage of prenatally diagnosed cases of CHD by year,
demonstrating a significant increase between 2003 and 2008 (p =
0.021).
Figure 2
The total number of cases of CHD in groups 1–5, along with the
number of prenatally diagnosed cases and their outcomes (live
birth, stillbirth, and TOP).
Vaud-Switzerland reported 1,599 cases of congenital an-
omalies, including 572 cases of CHD, resulting in an over-
all CHD prevalence of 137.6/10,000. In total, 37 cases were
excluded from our study (PFO, PDA, and anomalies con-
sidered as variations of the norm), resulting in a total of 535
CHD cases included in our study.
During the study period, 135 cases of CHD were diagnosed
prenatally, corresponding to a mean detection rate of
25.2%. The detection rate increased significantly between
the years 2003 and 2008 (from 15.4 to 33.7%, p = 0.021)
(fig. 1).
Figure 2 shows the total number of cases of CHD in each
severity group, along with the number of prenatally dia-
gnosed cases and their outcomes in each group. Group 1
Figure 3
The percentage of prenatally diagnosed CHD cases in groups 1–5.
Figure 4
The outcomes of pregnancies in groups 1–5 (live birth or stillbirth,
TOP for isolated CHD, or TOP for CHD associated with a
chromosomal or syndromal anomaly).
Table 2: Numbers of births, CHD cases, prenatally diagnosed CHD cases, and TOP decisions; total prevalence rates; and prevalence rates at birth for CHD (any CHD,
CHD after exclusion, non-chromosomal CHD, and group 1 CHD), as well as a comparison of total CHD and CHD prevalence rates at birth in the Canton of Vaud,
Switzerland (1.5.2003 to 31.12.2008).















572 137.6 119.6 0.023
CHD (after
exclusion*)




471 81 30 113.3 106.1 0.3178
Group 1 CHD
41573
32 28 24 7.7 1.9 <0.0001
CHD = congenital heart disease; LB = live births; SB, stillbirths; TOP = termination of pregnancy.
* Number of CHD cases after exclusion of patent foramen ovale, patent ductus arteriosus, and cases considered as variations of the norm.
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accounted for 6% of all CHD, group 2 for 1.1%, group 3
for 9.5%, group 4 for 15.1%, and group 5 for 68.2%.
The CHD cases included in the groups 1–4 were considered
significant in our study and accounted for 31.8% of all
CHD (170/535). The overall prenatal detection rate for
CHD in the first four groups (groups 1–4) was 51.8% (88/
170). Figure 3 shows the rates of prenatal diagnosis in the
different groups, with the highest detection rate (87.5%)
found in the group with the most severe CHD (group 1).
The detection rates in the groups 2 and 3 were 66% (group
2) and 68.6% (group 3), respectively, with a lower rate in
group 4 (25.9%). The fifth group consisted of 365 cases of
minor CHD with no impact on the outcome, and prenatal
diagnosis was the least frequent in this group (12.9%).
Approximately half of the prenatally diagnosed cases were
examined in our echocardiographic unit, and the other
cases were observed at primary or secondary centres or ter-
tiary centres outside the canton. Most of the cases that were
not referred to tertiary centres led to TOP due to associated
chromosomal, syndromal, or other major congenital anom-
alies, and post-mortem examination results were available
in 68% of the TOP cases.
Group 1 consisted of 32 cases, 87.5% of which were de-
tected antenatally, leading to TOP in 85.7% of the cases. A
total of 46% cases were associated with a chromosomal or
other anomaly.
In groups 2–5, the proportion of TOP varied among the dif-
ferent groups: 33.3% in group 2, 43.1% in group 3, 12%
in group 4 and 4.6% in group 5. All TOP procedures were
performed due to associated chromosomal, syndromal, or
other major congenital anomalies, with the exception of
one case of truncus arteriosus (fig. 4).
In group 3, 66% of CHD cases were associated with chro-
mosomal, syndromal, or other major congenital anomalies
(34/51). The rate of prenatal diagnosis in this group was
68.6%, and the rate was even higher in the case of as-
sociated anomalies (75.6%). In particular, atrioventricular
septal defect (AVSD) was associated in 90.9% of cases
with other anomalies (mostly chromosomal), and the rates
of prenatal diagnosis and TOP in this subgroup were 86%
and 68%, respectively.
In total, 88% of CHD cases were not associated with a
chromosomal anomaly, yielding an overall non-chromo-
somal CHD prevalence rate of 113.3/10,000 and a preval-
ence rate at birth of 106.1/10,000 (table 2). Most were live
births, and 78.5% were isolated CHD cases.
The overall prevalence rate of CHD during the study period
was 137.6/10,000, and the rate was 128.6/10,000 after ex-
cluding cases of PFO and PDA (table 2). In the specific
groups, the overall CHD prevalence rates were 7.7/10,000
in group 1, 1.4/10,000 in group 2, 12.3/10,000 in group 3,
19.5/10,000 in group 4, and 87.8/10,000 in group 5. Addi-
tionally, the prevalence rates at birth were 110.9/10,000 for
all CHD cases, 106.1/10,000 for non-chromosomal CHD
cases, and 1.9/10,000 for group 1 CHD cases. In group 1,
the rate of CHD at birth was significantly lower than the
overall prevalence rate (table 2).
Discussion
This was a retrospective study on the effect of a prenatal
screening programme on the prevalence of congenital car-
diac malformations at birth in a small but well-defined pop-
ulation. This study differs from previous studies because
of its highly accurate epidemiological data. The Eurocat
Registry of Vaud provided data on all cases with a dia-
gnosis of cardiac congenital malformation (stillbirth, live
birth, and TOP, including CHD diagnosed up to 1 year of
life), and our tertiary care centre provided precise foetal
and neonatal data for our cases. The total prevalence rate
of CHD during the study period was 137.6/10,000, which
is considerably higher than the previously reported preval-
ence. Van der Linde et al. showed a gradual increase of
<1% in the incidence of congenital heart defects over time
[11]. However, prevalence rates similar to ours were repor-
ted by Dolk et al. in 2011 [5]. This increased prevalence
may be due to the over-reporting of intrauterine-diagnosed
defects that correct themselves at term, such as a prenat-
ally diagnosed muscular ventricular septal defect (VSD),
which tends to close before birth [12]. Another explanation
could be a higher rate of high-risk pregnancies, such as ma-
ternal diabetes associated with septal hypertrophy during
pregnancy [13].
We observed a significant increase in prenatally diagnosed
CHD between 2003 and 2008, likely due to our organised
and focused training efforts, including outreach teaching
courses. These efforts led to increased awareness and better
knowledge of the diagnostic tools available in our obstetric
community [2, 8, 14–16].
Improved imaging technology may also have contributed
to our success. Although our study shows prenatal diagnos-
is rates similar to those in previous studies [2, 3, 17, 18],
the present study shows a clearer relationship between the
severity of CHD and the decision to terminate the preg-
nancy. For example, in 1999, Bull et al. reported a prenatal
detection rate of 66–69% for hypoplastic left heart and uni-
ventricular heart [2], and our study revealed a prenatal de-
tection rate of 88% for group 1 CHD cases. However, the
proportion of parents deciding to terminate the pregnancy
remained consistent over time. This result could mean that
despite the improvement of the diagnostic and therapeutic
armamentarium, parents' perceptions of the future quality
of life of their offspring have remained unchanged.
Counselling parents after prenatal diagnosis of CHD is
therefore an important task for our multidisciplinary team,
and the prognosis will be based on not only the diagnosis
itself but also its accuracy; the gestational age at diagnosis;
any association with extracardiac malformation; and the
known results of treatment options, including local surgical
results. If parents decide to terminate the pregnancy, we
suggest a period of reflection of 2–3 days, which could be
implemented to ensure a prudent decision (the minimum
time accepted would be 24 hours in special cases). In
Switzerland, TOP is practised until the age of viability (24
weeks of gestation). The parental choice regarding TOP in
cases of severe heart disease varies among different groups
of parents, depending on socio-religious background, edu-
cational status, and geographical location, with large dif-
ferences especially identified between the US and Europe
Original article Swiss Med Wkly. 2014;144:w14068
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[19]. In Switzerland, the rate of termination matches the
rates reported in France [20] and the UK [2] but is higher
than those in the Czech Republic [17] and The Netherlands
[19].
The division of CHD cases into groups was based on the
severity of CHD and an immediate need for intervention.
Transposition of the great arteries (TGA) was evaluated
separately, considering the high risk of immediate postnatal
morbidity and mortality [2].
In the most severe group (group 1), in which only palliative
intervention could be offered, TOP was prevalent, occur-
ring in 86% of cases. This choice can be explained by the
prospect of a limited quality of life and frequently associ-
ated complications, including the need for multiple opera-
tions, the risk of neuro-developmental delay, protein-losing
enteropathy, arrhythmias, cirrhosis, and thromboembolic
events, and the need for cardiac transplantation. These
complications have all been observed and reported in long-
term follow-up studies [21–33].
The in-hospital delivery option for babies with prenatally
diagnosed CHD allows immediate neonatal treatment and
prevention of hypoxia and cerebral damage [34–37]. Al-
though the limited size of our study did not allow definitive
conclusions regarding in-hospital delivery, previous pub-
lications were conclusive [38].
In groups 2–5, the number of terminations was limited and
occurred nearly exclusively in cases of foetuses with asso-
ciated chromosomal, syndromal, or other major congenital
anomalies (fig. 3) [39].
Neonates in group 5, with minor CHD, were less frequently
prenatally diagnosed, but this had no impact on their out-
come.
The Eurocat Registry provided data on all CHD anomalies
registered and on whether the anomalies were detected
prenatally, permitting us to calculate the percentage of
prenatally diagnosed cases of CHD in the population of the
Canton of Vaud. However, these data did not allow any
conclusion regarding the specificity of prenatal screening,
as the real number of all false-positive cases was not as-
sessed for this population.
The impact of the prenatal diagnosis of CHDs in general
paediatric cardiology practise is important. In countries
where prenatal sonographic evaluation is standard practise,
a measurable reduction in the prevalence of live births with
CHD has already been demonstrated [2, 40]. In particular,
Germanakis et al. calculated an assumed overall reduction
of 15% in the prevalence of the most severe malformations
[40]. Our study showed a significant reduction (14%) in the
overall CHD prevalence and a difference of 6.4% when ex-
cluding cases with chromosomal anomalies. The impact of
prenatal diagnosis on the prevalence rate at birth was the
highest in group 1. Although this study did not investigate
the direct changes in the number of surgical interventions,
we can assume that if this result is accurate, prenatal dia-
gnosis must have a significant impact on the care of pa-
tients with CHD. Additionally, it is likely that all of these
factors can lead to a change in the paediatric population
with congenital cardiac disease.
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Figures (large format)
Figure 1
The percentage of prenatally diagnosed cases of CHD by year, demonstrating a significant increase between 2003 and 2008 (p = 0.021).
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Figure 2
The total number of cases of CHD in groups 1–5, along with the number of prenatally diagnosed cases and their outcomes (live birth, stillbirth,
and TOP).
Original article Swiss Med Wkly. 2014;144:w14068
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 9
Figure 3
The percentage of prenatally diagnosed CHD cases in groups 1–5.
Figure 4
The outcomes of pregnancies in groups 1–5 (live birth or stillbirth, TOP for isolated CHD, or TOP for CHD associated with a chromosomal or
syndromal anomaly).
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